MBRX - Moleculin Biotech, Inc.

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
1.1800
-0.0200 (-1.67%)
At close: 4:00PM EDT

1.1800 0.00 (0.00%)
After hours: 5:42PM EDT

Stock chart is not supported by your current browser
Previous Close1.2000
Open1.1900
Bid1.1400 x 800
Ask1.2000 x 3200
Day's Range1.1500 - 1.2100
52 Week Range0.7770 - 3.1500
Volume399,906
Avg. Volume4,195,144
Market Cap53.327M
Beta (3Y Monthly)2.09
PE Ratio (TTM)N/A
EPS (TTM)-0.5120
Earnings DateAug 12, 2019 - Aug 16, 2019
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est5.50
Trade prices are not sourced from all markets
  • Benzinga2 days ago

    Moleculin Investors Rewarded As Annamycin Trial Advances To Next Cohort

    Moleculin Biotech Inc (NASDAQ: MBRX) announced positive data Thursday from its Phase 1/2 study of annamycin in Poland. Annamycin is an anthracycline antibiotic being investigated for the treatment of cancer. The company said intends to advance the clinical study of Annamycin to the next dose level.

  • PR Newswire2 days ago

    Moleculin Announces Annamycin in Acute Myeloid Leukemia in Poland Advances to 3rd Cohort

    HOUSTON, July 18, 2019 /PRNewswire/ -- Moleculin Biotech, Inc., (MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors, today announced additional positive interim safety and efficacy data from its ongoing open label, single arm Phase 1/2 study of Annamycin in Poland. Three patients were treated at dose level of 150 mg/m2 with no drug-related adverse events, including no signs of cardiotoxicity.

  • Moleculin Files New Patents for Cancer Candidate Annamycin
    Zacks9 days ago

    Moleculin Files New Patents for Cancer Candidate Annamycin

    Moleculin (MBRX) petitions for new patents to cover annamycin, currently being developed for treating patients with relapsed or refractory acute myeloid leukemia. Shares rise.

  • Benzinga10 days ago

    Moleculin Rallies On Patent Applications That Could Give Cancer Drug 20 Years of Protection

    Moleculin Biotech Inc (NASDAQ: MBRX )'s stock was advancing Wednesday on heavy volume. Moleculin, which focuses on drugs targeting highly resistant tumors, said it has filed new patents covering the production ...

  • PR Newswire10 days ago

    Moleculin Files for New Patents for Annamycin After Receiving FDA Approval of Fast Track Designation

    HOUSTON, July 10, 2019 /PRNewswire/ -- Moleculin Biotech, Inc. (MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors, today announced it has filed new patents covering the production and reconstitution of Annamycin, which is currently in two clinical trials for the treatment of relapsed or refractory acute myeloid leukemia (AML).

  • What Type Of Shareholder Owns Moleculin Biotech, Inc.'s (NASDAQ:MBRX)?
    Simply Wall St.2 months ago

    What Type Of Shareholder Owns Moleculin Biotech, Inc.'s (NASDAQ:MBRX)?

    If you want to know who really controls Moleculin Biotech, Inc. (NASDAQ:MBRX), then you'll have to look at the makeup...

  • PR Newswire2 months ago

    Moleculin Biotech, Inc. Reports Financial Results for the First Quarter Ended March 31, 2019

    HOUSTON, May 14, 2019 /PRNewswire/ -- Moleculin Biotech, Inc. (MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors, today announced its financial results for the first quarter ended March 31, 2019. Additionally, the Company announced potential upcoming milestones and recent corporate developments. This time last year we had just commenced our first clinical trial for one drug.  Today, we have three drugs in four clinical trials under way with a fifth clinical trial that may start before year end.

  • PR Newswire2 months ago

    Moleculin Announces Additional Positive Interim Results in First Cohort of Phase 1/2 Clinical Studies of Annamycin in Acute Myeloid Leukemia in Europe

    2 of 3 patients qualify to proceed to a potentially curative bone marrow transplant; trial advances to next higher dose level HOUSTON , May 7, 2019 /PRNewswire/ -- Moleculin Biotech, Inc., (Nasdaq: MBRX) ...

  • PR Newswire3 months ago

    Generex Biotechnology Announces Organizational Roadmap & Investor Conference Call: Update on Product Launch, New Acquisitions, Financing, Expansion Initiatives & Strategic Plans

    Generex Biotechnology Corporation (www.generex.com) (GNBT) (http://www.otcmarkets.com/stock/GNBT/quote) today announced that the company has scheduled an investor conference call for May 15, 2019 with Joseph Moscato, President & Chief Executive Officer of Generex who will present an organizational roadmap outlining Generex Biotechnology's operational, strategic and financial plans, as outlined herein.

  • Positive Results From HMN Lithium Project P.E.A.
    CNW Group3 months ago

    Positive Results From HMN Lithium Project P.E.A.

    Positive Results From HMN Lithium Project P.E.A.

  • PR Newswire3 months ago

    US Biopharma Company Undertakes Anti-Cancer Clinical Trials in Poland, First Patient Showing Positive Initial Treatment

    Moleculin quickly recruited qualified patients and started trials for two of its portfolio drugs to supplement US efforts. HOUSTON, April 29, 2019 /PRNewswire/ -- A small public company with 6 highly promising anti-cancer drugs in the pipeline is augmenting US clinical trials with trials in Poland, speeding the process of patient recruitment and data collection. The company, Moleculin (MBRX), recently recruited 3 patients in 6 weeks in Poland, whereas in the U.S. it took a full year to build a similar, complete cohort.

  • PR Newswire3 months ago

    Moleculin Announces $15.0 Million Registered Direct Offering

    HOUSTON, April 23, 2019 /PRNewswire/ -- Moleculin Biotech, Inc., (MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors, today announced that it has entered into definitive agreements with institutional investors to purchase an aggregate of 9,375,000 units at a public offering price of $1.60 per unit in a registered direct offering. The offering is expected to close on or about April 25, 2019, subject to customary closing conditions. The gross proceeds of the offering are expected to be approximately $15.0 million, prior to deducting the placement agent fees and other estimated offering expenses.

  • Benzinga3 months ago

    The Daily Biotech Pulse: FDA Accepts Alder's Migraine Drug Application, Gritstone Offering, Lilly's Chinese Sale

    Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on April 22) Moleculin Biotech Inc (NASDAQ: MBRX ) (announcement ...

  • PR Newswire3 months ago

    Moleculin Announces Conference Call to Discuss Significant Discovery For Lung Cancer and FDA Activity on Wednesday, April 24, 2019

    HOUSTON , April 22, 2019 /PRNewswire/ -- Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a broad portfolio of drug ...

  • PR Newswire3 months ago

    Moleculin Receives FDA Approval of Fast Track Designation for Annamycin

    HOUSTON, April 18, 2019 /PRNewswire/ -- Moleculin Biotech, Inc., (MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors, today announced that the U.S. Food and Drug Administration ("FDA") has approved its request for Fast Track Designation for its drug, Annamycin, for the treatment of relapsed or refractory acute myeloid leukemia ("AML").

  • PR Newswire3 months ago

    Moleculin Announces Significant Discovery in Lung Cancer Models

    "We know that Annamycin was previously shown to be significantly more potent than doxorubicin in both Lewis lung carcinoma in vivo and small cell lung cancer in vitro models," commented Walter Klemp, Moleculin's Chairman and CEO. "Now we are seeing significant activity against triple negative breast cancer that has metastasized to the lungs.

  • PR Newswire3 months ago

    Moleculin Announces Agreement with Emory University to Conduct Pediatric Brain Tumor Trial

    HOUSTON, April 11, 2019 /PRNewswire/ -- Moleculin Biotech, Inc., (MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors, today announced it has entered into an agreement with Emory University to conduct a Phase 1 clinical trial of WP1066 in children with recurrent or refractory malignant brain tumors. "Given the exciting data Emory University researchers presented at the recent Society for Neuro Oncology conference, we have been working closely with them to begin a trial in pediatric brain tumors," commented Walter Klemp, Moleculin's Chairman and CEO. This will also give us yet another opportunity to develop human proof of concept data, bringing our total number of clinical trials to five.

  • PR Newswire3 months ago

    Moleculin Announces Successful Expansion of its Leukemia Drug Program

    HOUSTON, April 9, 2019 /PRNewswire/ -- Moleculin Biotech, Inc., (MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors, today announced it has successfully expanded the clinical supply of Annamycin for its on-going clinical trials via BSP Pharmaceuticals S.p.A. (www.bsppharmaceuticals.com) in Latina, Italy. "Securing production supply for a liposomal anthracycline like Annamycin is no trivial matter, which is why we partnered last year with a quality supplier like BSP, who will be able to supply Annamycin in commercial quantities going forward," commented Walter Klemp, Moleculin's Chairman and CEO.

  • PR Newswire4 months ago

    Moleculin Announces Preclinical Pancreatic Cancer Data Presented at American Association for Cancer Research Annual Meeting

    The presentation included data resulting from preclinical evaluation in pancreatic cancer models of STAT3 inhibitors WP1066 and WP1732, both discovered at The University of Texas MD Anderson Cancer Center and licensed by Moleculin. WP1066 is an orally bioavailable drug with significant brain uptake that is currently in Phase I clinical studies in patients with brain tumors.

  • PR Newswire4 months ago

    EnerCube Completes Complex Design Project With Altasteel

    TORONTO, April 1, 2019 /PRNewswire/ -- CellCube Energy Storage Systems Inc. ("CellCube" or the "Company") (CSE CUBE) (CUBE.CN) (CECBF) (Frankfurt 01X, WKN A2JMGP) on behalf of its wholly-owned subsidiary, EnerCube Switchgear Systems Inc. ("EnerCube") is pleased to announce EnerCube has completed a significant sale and complex switchgear upgrade to the AltaSteel plant. AltaSteel is a Canadian manufacturer of prime quality steel products for the mining, construction, automotive and engineering industries based in Edmonton, Alberta.

  • PR Newswire4 months ago

    Moleculin Announces Pricing Of Underwritten Public Offering

    HOUSTON, March 27, 2019 /PRNewswire/ -- Moleculin Biotech, Inc., (MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors, today announced the pricing of an underwritten public offering of an aggregate of 5,250,000 units at a public offering price of $1.00 per unit. Each unit is comprised of one share of common stock and 0.5 of a warrant to purchase one share of common stock for a total of 5,250,000 shares of common stock and warrants to purchase 2,625,000 shares of common stock.

  • PR Newswire4 months ago

    Moleculin Announces Proposed Underwritten Public Offering

    The Company intends to use the net proceeds of the offering to fund its planned clinical trials, preclinical programs, for other research and development activities and for general corporate purposes. The securities described above are being offered by the Company pursuant to a shelf registration statement on Form S-3 (No. 333-219434) previously filed with and declared effective by the Securities and Exchange Commission (SEC).  A preliminary prospectus supplement and the accompanying prospectus relating to and describing the terms of the offering will be filed with the SEC and will be available on the SEC's website at http://www.sec.gov.

  • PR Newswire4 months ago

    Moleculin Announces Positive Interim Results in First Cohort of Phase 1/2 Clinical Studies of Annamycin in Acute Myeloid Leukemia in the US and in Poland

    HOUSTON, March 26, 2019 /PRNewswire/ -- Moleculin Biotech, Inc., (MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors, today announced positive interim safety and efficacy data from two ongoing open label, single arm Phase 1/2 studies of Annamycin.  In the first study, being conducted in the US, four patients have completed treatment at 100 mg/m2 with no significant adverse events related to Annamycin, and the study will now proceed to the next higher dose of 120 mg/m2. The second trial, taking place in Poland, started at a 120 mg/m2 dose of Annamycin and has treated three patients.

  • PR Newswire4 months ago

    Moleculin Announces First Patients Enrolled in Lymphoma Clinical Trial

    HOUSTON, March 19, 2019 /PRNewswire/ -- Moleculin Biotech, Inc., (MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors, today announced that the first two patients have been enrolled in its European clinical trial of WP1220 for the topical treatment of cutaneous T-cell lymphoma (CTCL). "This now marks four clinical trials with patients enrolled," commented Walter Klemp, Moleculin's Chairman and CEO. "In this case, we are targeting CTCL with a topical p-STAT3 inhibitor in light of the significant role that STAT3 appears to play in CTCL skin lesions.

  • PR Newswire4 months ago

    Moleculin Announces Memorial Sloan Kettering Chief of Leukemia Joins Science Advisory Board

    HOUSTON , March 18, 2019 /PRNewswire/ -- Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a broad portfolio of drug ...